Zydus Lifesciences Ltd gets 3 observations from USFDA for Injectable Facility

Zydus Lifesciences Ltd., today announced that the group's injectable facility at Jarod underwent a USFDA inspection from 24th February to 10th March, 2022. The inspection closed with three observations.

We are confident of addressing and resolving the issues to the satisfaction of USFDA. We remain committed to building a quality culture across our entire manufacturing network, and are committed to remain compliant with high standards of Good Manufacturing Practices across our network.

Shares of Cadila Healthcare Limited was last trading in BSE at Rs. 365.70 as compared to the previous close of Rs. 359.85. The total number of shares traded during the day was 69977 in over 3162 trades.

The stock hit an intraday high of Rs. 367.75 and intraday low of 361.50. The net turnover during the day was Rs. 25496612.00.

Source : Equity Bulls

Keywords

ZydusLifesciences CadilaHealthcare INE010B01027 USFDAInspection Observations InjectableFacility Jarod